|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12...345678910111213...6768» |
- | Trial completion: Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome (clinicaltrials.gov) - May 15, 2017
P=N/A, N=50, Completed, Sponsor: University of Zurich
Recruiting --> Completed
- fidanacogene elaparvovec (PF-06838435) / Pfizer
Phase classification, Gene therapy, Viral vector: Hemophilia B Gene Therapy With AAV8 Vector (clinicaltrials.gov) - May 12, 2017
P1, N=4, Terminated, Sponsor: Spark Therapeutics
Recruiting --> Completed Phase classification: P1/2 --> P1
- | DTX101 / Ultragenyx
Enrollment closed: Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B (clinicaltrials.gov) - May 11, 2017
P1/2, N=12, Active, not recruiting, Sponsor: Dimension Therapeutics
Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting
- | Innohep (tinzaparin) / LEO Pharma
Trial completion: METRO B: Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (clinicaltrials.gov) - May 11, 2017
P2, N=19, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial primary completion date: MOrPH: Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia (clinicaltrials.gov) - May 9, 2017
P=N/A, N=20, Enrolling by invitation, Sponsor: Neuroscience Research Australia
Recruiting --> Completed Trial primary completion date: Nov 2016 --> Dec 2017
- | plerixafor / Generic mfg.
Biomarker, Trial primary completion date, Tumor microenvironment: Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (clinicaltrials.gov) - May 9, 2017
P1, N=7, Terminated, Sponsor: Tufts Medical Center
Trial primary completion date: Nov 2016 --> Dec 2017 Trial primary completion date: Mar 2017 --> Jun 2014
- | simvastatin / Generic mfg.
Enrollment change, Trial withdrawal: Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 9, 2017
P, N=0, Withdrawn, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Mar 2017 --> Jun 2014 N=35 --> 0 | Not yet recruiting --> Withdrawn
- || azintuxizumab vedotin (ABBV-838) / AbbVie
Clinical: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2017
P1, N=161, Active, not recruiting, Sponsor: AbbVie
N=35 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | Trial completion: Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry (clinicaltrials.gov) - May 4, 2017
P=N/A, N=28, Completed, Sponsor: University of Valencia
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma (clinicaltrials.gov) - May 3, 2017
P2, N=32, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Terminated --> Active, not recruiting
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment change, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - May 2, 2017
P=N/A, N=104, Active, not recruiting, Sponsor: Pfizer
Terminated --> Active, not recruiting N=140 --> 104
- oprozomib (ONX 0912) / Amgen
Phase classification: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 2, 2017
P1b/2, N=9, Completed, Sponsor: Amgen
N=140 --> 104 Phase classification: P1/2 --> P1b/2
- | lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients (clinicaltrials.gov) - May 2, 2017
P2, N=32, Active, not recruiting, Sponsor: University Health Network, Toronto
Phase classification: P1/2 --> P1b/2 Trial primary completion date: Apr 2017 --> Aug 2017
- |||| carfilzomib / Generic mfg.
P2 data: Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma (clinicaltrials.gov) - May 2, 2017
P2, N=164, Completed, Sponsor: Amgen
Trial primary completion date: Apr 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Nov 2011 --> Jan 2013
- ||| Trial completion, HEOR: A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=221, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Nov 2011 --> Jan 2013 Active, not recruiting --> Completed
- staphylococcal protein A (PRTX-100) / Protalex
Phase classification, Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Apr 28, 2017
P1b, N=30, Recruiting, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed Phase classification: P1/2 --> P1b | Trial primary completion date: Jun 2017 --> Dec 2017
- | Esperoct (turoctocog alfa pegol) / Novo Nordisk
Trial completion, M&A: A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (clinicaltrials.gov) - Apr 28, 2017
P1, N=21, Completed, Sponsor: Novo Nordisk A/S
Phase classification: P1/2 --> P1b | Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma (clinicaltrials.gov) - Apr 27, 2017
P1b/2, N=101, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Oct 2016
- | Trial completion, Enrollment change, Surgery: PASs: Inhibitor Development in Patients With Hemophilia A Undergoing Surgery (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=30, Completed, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Oct 2016 Active, not recruiting --> Completed | N=140 --> 30
- | Enrollment change: Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome (clinicaltrials.gov) - Apr 26, 2017
P1, N=4, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=140 --> 30 N=12 --> 4
- | Trial primary completion date: Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=75, Completed, Sponsor: Stanford University
N=12 --> 4 Trial primary completion date: Jul 2014 --> Feb 2017
- ||||| ATryn (antithrombin) / LFB Biotechnologies, Knight Therap
Trial initiation date: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients (clinicaltrials.gov) - Apr 25, 2017
P, N=10, Not yet recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jul 2014 --> Feb 2017 Initiation date: Jan 2017 --> Jul 2017
- Farydak (panobinostat) / Secura Bio
Clinical: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat (clinicaltrials.gov) - Apr 25, 2017
P1/2, N=0, Withdrawn, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Jan 2017 --> Jul 2017 N=85 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion, Surgery: INWOUND: Wound Healing Abnormalities in Major Abdominal Surgery (clinicaltrials.gov) - Apr 24, 2017
P=N/A, N=260, Completed, Sponsor: Klinikum St. Georg gGmbH
N=85 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Trial primary completion date: Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia (clinicaltrials.gov) - Apr 20, 2017
P2, N=7, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=60 --> 7 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Feb 2016; The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug.
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 18, 2017
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 7 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Feb 2016; The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug. Trial primary completion date: Dec 2016 --> Dec 2017
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Dec 2017 N=200 --> 41
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial primary completion date: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Apr 14, 2017
P2, N=49, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=200 --> 41 Trial primary completion date: Apr 2017 --> Jun 2014
- | marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Clinical: Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2017
P1, N=38, Completed, Sponsor: Triphase Research and Development I Corporation
Trial primary completion date: Apr 2017 --> Jun 2014 Active, not recruiting --> Completed
- |||| Empliciti (elotuzumab) / AbbVie, BMS
Trial completion, Phase classification, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2017
P2a, N=51, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P2 --> P2a
- | Empliciti (elotuzumab) / AbbVie, BMS, Decadron (dexamethasone) / Merck (MSD)
Enrollment change, Trial withdrawal, IO biomarker: 2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy (clinicaltrials.gov) - Apr 14, 2017
P2, N=0, Withdrawn, Sponsor: University of Arkansas
Active, not recruiting --> Completed | Phase classification: P2 --> P2a N=200 --> 0 | Not yet recruiting --> Withdrawn
- | carfilzomib / Generic mfg.
Clinical: Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease (clinicaltrials.gov) - Apr 11, 2017
P1, N=26, Completed, Sponsor: Onyx Therapeutics, Inc.
N=200 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Initiation date: Oct 2013 --> Jan 2014
- ||| gandotinib (LY 2784544) / Eli Lilly
Trial completion: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - Apr 11, 2017
P1, N=100, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Initiation date: Oct 2013 --> Jan 2014 Active, not recruiting --> Completed
- | Trial termination, Trial primary completion date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Apr 11, 2017
P2, N=144, Terminated, Sponsor: Denver Health and Hospital Authority
Active, not recruiting --> Completed Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017; Futility
- | Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Surgery: Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=0, Withdrawn, Sponsor: Boston Children’s Hospital
Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017; Futility N=50 --> 0 | Initiation date: Jan 2015 --> Apr 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2015 --> Apr 2017
- | carfilzomib / Generic mfg.
P1/2 data: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P1b/2, N=184, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
N=50 --> 0 | Initiation date: Jan 2015 --> Apr 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2015 --> Apr 2017 Phase classification: P1/2 --> P1b/2
- | bortezomib / Generic mfg.
Trial completion, Enrollment change: Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Apr 7, 2017
P2, N=46, Completed, Sponsor: Guido Tricot
Phase classification: P1/2 --> P1b/2 Active, not recruiting --> Completed | N=204 --> 46
- marzeptacog alfa (CB 813d) / GC Biopharma
Enrollment change, Trial primary completion date: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - Apr 7, 2017
P1, N=29, Completed, Sponsor: Catalyst Biosciences
Active, not recruiting --> Completed | N=204 --> 46 N=24 --> 29 | Trial primary completion date: Feb 2015 --> Oct 2015
- | Trial completion, Enrollment change, Trial primary completion date: Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=33, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=24 --> 29 | Trial primary completion date: Feb 2015 --> Oct 2015 Suspended --> Completed | N=75 --> 33 | Trial primary completion date: Dec 2015 --> Sep 2014
- | Trial completion: Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=27, Completed, Sponsor: Oregon Health and Science University
Suspended --> Completed | N=75 --> 33 | Trial primary completion date: Dec 2015 --> Sep 2014 Active, not recruiting --> Completed
- | Trial completion: Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=5, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Mar 31, 2017
P1/2, N=154, Completed, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Trial primary completion date: Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Mar 31, 2017
P2, N=14, Terminated, Sponsor: University of Arizona
Active, not recruiting --> Completed Trial primary completion date: Nov 2009 --> Apr 2009
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment closed: Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=600, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Nov 2009 --> Apr 2009 Not yet recruiting --> Active, not recruiting
- Esperoct (turoctocog alfa pegol) / Novo Nordisk
Enrollment closed, M&A: A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (clinicaltrials.gov) - Mar 29, 2017
P1, N=22, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | BeneFix (nonacog alfa) / Pfizer
New P2 trial: Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B (clinicaltrials.gov) - Mar 27, 2017
P2, N=13, Completed, Sponsor: Grifols Biologicals Inc.
- | Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Enrollment change: A Clinical Study of KW-3357 in Patients With DIC (clinicaltrials.gov) - Mar 24, 2017
P3, N=15, Completed, Sponsor: Kyowa Hakko Kirin Co., Ltd
Recruiting --> Active, not recruiting N=10 --> 15
- | lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date: Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients (clinicaltrials.gov) - Mar 23, 2017
P2, N=32, Active, not recruiting, Sponsor: University Health Network, Toronto
N=10 --> 15 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- || melphalan / Generic mfg., carfilzomib / Generic mfg.
BRCA Biomarker: Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=58, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- | Trial completion: Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers (clinicaltrials.gov) - Mar 20, 2017
P=N/A, N=30, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Nov 2016 --> Nov 2017 Active, not recruiting --> Completed